Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NEIL LIN KAO

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1720089477
CMS profile
32539
Location
GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,148.95

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,954.18 123
Travel and Lodging $194.77 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NEIL LIN KAO

NPI 1720089477 · CMS profile ID 32539

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720089477?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NEIL LIN KAO, NPI 1720089477, CMS profile ID 32539. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720089477?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NEIL LIN KAO, NPI 1720089477, CMS profile ID 32539. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720089477?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NEIL LIN KAO, NPI 1720089477, CMS profile ID 32539, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1720089477?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $3,148.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–124 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $10.1002/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997602491 CMS
PFIZER INC. $14.1302/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049412811 CMS
AstraZeneca Pharmaceuticals LP $17.3302/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025033859 CMS
Grifols USA, LLC $18.5102/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809259 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.4502/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055424755 CMS
AstraZeneca Pharmaceuticals LP $100.3102/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025018399 CMS
GENZYME CORPORATION $23.7402/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049743461 CMS
GENZYME CORPORATION $20.6702/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049743431 CMS
Amgen Inc. $17.5501/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020042677 CMS
AstraZeneca Pharmaceuticals LP $119.2601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024985951 CMS
AstraZeneca Pharmaceuticals LP $28.7401/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025041617 CMS
AstraZeneca Pharmaceuticals LP $56.7301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025053367 CMS
AstraZeneca Pharmaceuticals LP $30.0901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025062743 CMS
AstraZeneca Pharmaceuticals LP $194.7701/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025067795 CMS
AstraZeneca Pharmaceuticals LP $76.9901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025073491 CMS
PFIZER INC. $16.3901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049291113 CMS
GENZYME CORPORATION $12.8101/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049743443 CMS
AstraZeneca Pharmaceuticals LP $13.1801/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025041717 CMS
GlaxoSmithKline, LLC. $5.7201/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001166231 CMS
GlaxoSmithKline, LLC. $4.5601/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001166921 CMS
ABBVIE INC. $14.7001/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997602489 CMS
AstraZeneca Pharmaceuticals LP $173.3201/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024989902 CMS
GENZYME CORPORATION $9.4201/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049743395 CMS
GENZYME CORPORATION $10.1501/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049743419 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,593.68 109
PY2020 $2,394.94 83
PY2021 $2,257.33 114
PY2022 $2,157.04 112
PY2023 $3,148.95 124
PY2024 $3,503.45 147
PY2025 $4,642.19 152

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $234,496.60 338
PY2024 Principal investigator $198,958.61 314
PY2023 Principal investigator $263,371.10 129
PY2022 Principal investigator $225,959.04 35
PY2021 Principal investigator $240,737.24 40
PY2020 Principal investigator $224,016.09 41
PY2019 Principal investigator $291,477.30 51

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

338 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $383.00 12/24/2025 Non-covered Recipient Entity
Adac Research PA
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226138784
Principal investigator 1 SANOFI US SERVICES INC. $319.00 12/24/2025 Non-covered Recipient Entity
Adac Research PA
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable No dispute reported 06/30/2026 1226138789
Principal investigator 1 GENZYME CORPORATION $13,608.42 12/22/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 11/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184256987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 11/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184256989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 11/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184256991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 11/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184256993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251624
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184251634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252294
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252296
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252314
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252352
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252370
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 10/22/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184252438
Principal investigator 1 GENZYME CORPORATION $10,656.96 10/20/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 09/10/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184235813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184233878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184233880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184233882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,125.95 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64.80 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $472.50 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $708.75 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,460.75 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $583.25 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,417.50 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 09/03/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184234987
Principal investigator 1 Genentech, Inc. $500.00 08/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569706
Principal investigator 1 Genentech, Inc. $9,660.00 08/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569710
Principal investigator 1 Genentech, Inc. $1,000.00 08/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569713
Principal investigator 1 Genentech, Inc. $2,221.00 08/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569717
Principal investigator 1 Genentech, Inc. $1,000.00 08/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569720
Principal investigator 1 GENZYME CORPORATION $2,412.32 08/04/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138758
Principal investigator 1 GENZYME CORPORATION $1,906.24 08/04/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138761
Principal investigator 1 AstraZeneca UK Limited $191.14 07/09/2025 Non-covered Recipient Entity
ALLERGIC DISEASE AND ASTHMA CENTER, PA
BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist No dispute reported 06/30/2026 1185539753
Principal investigator 1 AstraZeneca UK Limited $13,075.00 07/02/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist No dispute reported 06/30/2026 1185539747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.16 06/30/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184212045
Principal investigator 1 GENZYME CORPORATION $10,716.96 06/16/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138755
Principal investigator 1 Novartis Pharmaceuticals Corporation $50,151.10 06/15/2025 Non-covered Recipient Entity
ALLERGIC DISEASE AND ASTHMA CENTER
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190306449
Principal investigator 1 GENZYME CORPORATION $540.00 05/27/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138750
Principal investigator 1 Genentech, Inc. $476.00 05/14/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569628
Principal investigator 1 Genentech, Inc. $1,011.00 05/14/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569633
Principal investigator 1 Genentech, Inc. $801.00 05/14/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569702
Principal investigator 1 GENZYME CORPORATION $1,448.48 05/12/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138746
Principal investigator 1 Genentech, Inc. $2,768.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569636
Principal investigator 1 Genentech, Inc. $5.46 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569641
Principal investigator 1 Genentech, Inc. $1,300.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569645
Principal investigator 1 Genentech, Inc. $1,011.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569649
Principal investigator 1 Genentech, Inc. $19.34 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569653
Principal investigator 1 Genentech, Inc. $57.14 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569656
Principal investigator 1 Genentech, Inc. $51.36 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569659
Principal investigator 1 Genentech, Inc. $90.03 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569668
Principal investigator 1 Genentech, Inc. $1,200.15 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569673
Principal investigator 1 Genentech, Inc. $5,283.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569677
Principal investigator 1 Genentech, Inc. $681.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569681
Principal investigator 1 Genentech, Inc. $275.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569686
Principal investigator 1 Genentech, Inc. $579.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569690
Principal investigator 1 Genentech, Inc. $50.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569693
Principal investigator 1 Genentech, Inc. $497.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184193147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184193189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184193231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184193291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 05/07/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184193299
Principal investigator 1 SANOFI US SERVICES INC. $2,509.00 05/05/2025 Non-covered Recipient Entity
Adac Research PA
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226138735
Principal investigator 1 GENZYME CORPORATION $1,700.00 04/28/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 04/23/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184186247
Principal investigator 1 Genentech, Inc. $131.00 04/02/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211569664
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,020.88 03/28/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185539751
Principal investigator 1 SANOFI US SERVICES INC. $383.00 03/24/2025 Non-covered Recipient Entity
Adac Research PA
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226138738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174648
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/19/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184174694
Principal investigator 1 GENZYME CORPORATION $3,277.12 03/17/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $604.80 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $708.75 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $472.50 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $708.75 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $472.50 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.10 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.65 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 03/06/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157479
Principal investigator 1 SANOFI US SERVICES INC. $14,600.00 03/04/2025 Non-covered Recipient Entity
Adac Research PA
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226138717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 02/27/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184156020
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,066.36 02/24/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185539745
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,240.09 02/24/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States No dispute reported 06/30/2026 1185539749
Principal investigator 1 GENZYME CORPORATION $360.00 02/18/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138725
Principal investigator 1 GENZYME CORPORATION $3,477.28 02/18/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138728
Principal investigator 1 GENZYME CORPORATION $1,350.00 02/18/2025 Non-covered Recipient Entity
Adac Research PA
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $215.16 02/05/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $573.75 01/02/2025 Non-covered Recipient Entity
ADAC RESEARCH PA
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144686